Clinical Trial

Comparison of ESP Block and STAP Plane Block

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
In order to effectively manage postoperative analgesia in patients planned to undergo elective laparoscopic cholecystectomy, patients will be divided into 2 (two) groups and informed consent forms will be obtained after the necessary information is provided so that both groups can be included in the study. In the group planned to undergo erector spinae plane block, erector spinae plane block will be performed after monitoring and sedation in the operating room block unit before being taken to the surgical table preoperatively and postoperative PCA analgesia will be applied. In patients who will undergo subcostal transversus abdominis plane block, subcostal tap block will be performed after monitoring and sedation in the operating room block unit before being taken to the surgical table preoperatively and postoperative PCA analgesia will be applied. The patients' perioperative pain will be monitored with NOL (nociception level) monitor. Remifentanil dose will be adjusted to keep the NOL level between 10 and 25. After the patients are followed up for 24 hours postoperatively, their additional analgesia needs and amounts during this process will be compared. In this way, it is aimed to show that the analgesic method can be used effectively in the follow-up of pain management by comparing the Erector Spina Plane block and the Subcostal Transversus Abdominis Plane block as an effective analgesic application in laparoscopic cholecystectomy operations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-28.
Trial Details
NCT Number NCT06663449
Lead Sponsor Kocaeli University
Conditions Postoperative Pain
Enrollment 68 participants
Start Date 2024-12-15
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-05